Pharmacy E-News

Pharmacy E-News helps contracted network physicians obtain the latest drug information without drug company bias. The quarterly newsletter contains clinical information on pharmacy topics relevant to primary care, including evaluations of new drugs, reviews of significant published studies, and FDA safety warnings.

If you would like to be notified when the newsletter is published, or for more information about the articles, contact Galen Goertzen at 509-241-7572 or by e-mail at

May 2019 (PDF)

  • New preferred inhaled corticosteroid: Alvesco® (ciclesonide)
  • Impact of boosted anti-retroviral therapies on the Pharmacokinetics and Efficacy of Antiplatelet Agents
  • Kaiser Permanente Washington medication adherence services overview
  • Safety alert: Budesonide Respules (Pulmicort®)
  • FDA medication alert

February 2019 (PDF)

  • Aspirin for primary prevention in patients with diabetes
  • Important updates to hypertension guideline
  • Oral anticoagulant prescription trends in patients with Atrial Fibrillation
  • New requirements in opioid prescribing
  • FDA medication alert

November 2018 (PDF)

  • Comprehensive medication reviews associated with lower high-risk medication use
  • Identifying gluten-free medications
  • Current literature on cannabidiol-containing products
  • FDA safety alert: rare occurrences of a serious infection of the genital area

August 2018 (PDF)

  • Refresher on regular insulin U-500 administration
  • Evaluation of a pharmacist-managed diabetes program
  • Fluoroquinolone antibiotics: FDA requires labeling changes due to low blood sugar levels and mental health side effects
  • FDA safety alert: Potential risk of neural tube birth defects with HIV medicine dolutegravir (Juluca, Tivicay, Triumeq)